Covance bets on biologics; Pfizer eyeing CMOs for elevated role;

> While demand for preclinical research is flagging, Covance ($CVD) sees a way forward by focusing on biologics development. Article

> CRO MPI Research has launched a medical device evaluation service. News

> Pfizer ($PFE) is in the process of weeding through its more than 200 contract manufacturers to find the best among them for an elevated role. Story

> Six Australian CROs are joining forces to better compete for global clients, led by Sydney's Datapharm. More

> CRO Vince and Associates has joined the Altasciences Group, pooling its resources to provide early-phase research. Item

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.